Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

摘要: // Mariana Brait 1, * , Mithu Banerjee Leonel Maldonado 4 Akira Ooki 1 Myriam Loyo Elisa Guida Evgeny Izumchenko Leslie Mangold 2 Elizabeth Humphreys Eli Rosenbaum 5 Alan Partin David Sidransky 3 Mohammad Obaidul Hoque 2, Department of Otolaryngology and Head Neck Surgery, The Johns Hopkins University School Medicine, Baltimore, Maryland, USA Urology, Oncology, Pathology, South Alabama Medical Center, Mobile, Alabama, Urological Davidoff Beilinson Hospital, Eliahu Hakim, Ramat Aviv, Israel These authors contributed equally to this work Correspondence to: Hoque, email: mhoque1@jhmi.edu Keywords: prostate cancer, methylation, early detection Received: June 08, 2016      Accepted: December 31, Published: January 28, 2017 ABSTRACT Background: Prostate cancer (PC) is the second most common among men worldwide. Currently, non-invasive approach for screening risk assessment PC measuring level serum prostate-specific antigen (PSA). However, sensitivity PSA 42.8 % specificity 41.1%. As a result, test leads numerous unneeded biopsies. Therefore, rigorous search biomarkers ongoing. In study, we aim assess panel epigenetic markers in an intend develop PC. Results: hypermethylation MCAM was 66% 73% respectively which improvement from PSA. Considering combination marker MCAM, ERα ERβ increased 75% became 70% minimally invasive Materials Methods: Sixteen primary matched tumor were analyzed by quantitative methylation specific PCR (QMSP) determine analytical clinical genes tested ( SSBP2, ERα, ERβ, APC, CCND2, MGMT, GSTP1, p16 RARβ2 ). Additionally, samples eighty four cases PC, thirty controls seven diagnosed as high grade Prostatic Intraepithelial Neoplasia (HGPIN) analyzed. Conclusions: Promoter have potential be utilized biomarker their seem better than our cohort samples. After robust validation larger prospective cohort, findings may reduce numbers unwarranted